Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

ClinicalTrials.gov ID: NCT01073163

Public ClinicalTrials.gov record NCT01073163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).

Study identification

NCT ID
NCT01073163
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cephalon
Industry
Enrollment
54 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2010 (Type not available)
Primary completion
Jun 2012 (Actual)
Completion
Jun 2012 (Actual)
Last update posted
Apr 24, 2014

2010 – 2012

United States locations

U.S. sites
36
U.S. states
24
U.S. cities
35
Facility City State ZIP Site status
Hematology Oncology Physicans Extenders Group Tucson Arizona — —
University of Arkansas for Medical Sciences Little Rock Arkansas — —
St. Jude Heritage Medical Group Fullerton California — —
Comprehensive Cancer Center Palm Springs California — —
University of Colorado Cancer Center Aurora Colorado — —
Rocky Mountain Cancer Center Denver Colorado — —
The Hospital of Central Connecticut New Britain Connecticut — —
Cancer Center of Central Connecticut Southington Connecticut — —
Memorial Cancer Institute Hollywood Florida — —
Cancer Centers of Florida Orlando Florida — —
MD Anderson Cancer Cnt Orlando Orlando Florida — —
John B Amos Cancer Center Columbus Georgia — —
St Francis Cancer Research Foundation Beech Grove Indiana — —
Cedar Valley Medical Specialists Waterloo Iowa — —
Cancer Center of Kansas Wichita Kansas — —
University of Kentucky Lexington Kentucky — —
LSU Health Sciences Center - Shreveport Shreveport Louisiana — —
MaineGeneral Medical Center Augusta Maine — —
Missouri Cancer Associates Columbia Missouri — —
Kansas City Cancer Center Kansas City Missouri — —
UNM Cancer Center/New Mexico Cancer Care Alliance Albuquerque New Mexico — —
Interlakes Foundation, Inc Rochester New York — —
SUNY Upstate / Upstate Medical University Syracuse New York — —
Willamette Valley Cancer Center Springfield Oregon — —
Geisinger Medical Center Danville Pennsylvania — —
Pennsylvania Oncology Hematology Associates, Inc. Philadelphia Pennsylvania — —
Charleston Hematology Oncology, PA Charleston South Carolina — —
Sarah Cannon Cancer Center Nashville Tennessee — —
Texas Oncology, P.A. Fort Worth Texas — —
Cancer Care Center of South Texas San Antonio Texas — —
Texas Oncology Tyler Texas — —
Virginia Oncology Associates Norfolk Virginia — —
Cancer Outreach Asscociates, PC Richlands Virginia — —
Cancer Care Northwest-South Spokane Washington — —
Northwest Cancer Specialists, PC Vancouver Washington — —
West Virginia University School of Medicine Morgantown West Virginia — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01073163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2014 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01073163 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →